Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets

v3.7.0.1
Other Intangible Assets
3 Months Ended
Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangible Assets

4. OTHER INTANGIBLE ASSETS

 

The net carrying value of the identifiable intangible assets as of March 31, 2017 and December 31, 2016 are as follows:

 

          As of March 31, 2017     As of December 31, 2016  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
Diagnostic assets:                        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
Pancreas     -       -       -  
Biobank     -       -       -  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       18,351       18,351  
Total           $ 43,011     $ 43,011  
Diagnostic lab:                        
CLIA Lab     2.3     $ 609     $ 609  
                         
Accumulated Amortization           $ (8,075 )   $ (7,262 )
                         
Net Carrying Value           $ 35,545     $ 36,358  

 

Amortization expense was approximately $0.8 million and $1.0 million for the three-month periods ended March 31, 2017 and 2016, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2017     2018     2019     2020     2021  
$ 4,272     $ 5,292     $ 5,292     $ 5,292     $ 4,908